We are a Swiss law firm, dedicated to providing legal solutions to business, tax and regulatory matters.
Life Sciences, Pharma, Biotech
Litigation and Arbitration
Our knowledge, expertise & publications
Deals & Cases
26 October 2022
Oculis, SA, a global biopharmaceutical company developing treatments to save sight and improve eye care with breakthrough innovations and European Biotech Acquisition Corp (NASDAQ: EBAC), a special purpose acquisition company (SPAC), announced they have entered into a definitive busi-ness combination agreement. Upon closing of the transaction, the company will be named “Oculis Holding SA” and will work to accelerate the development of Oculis’s differentiated ophthalmology pipeline. The transaction includes commitments to an upsized PIPE and private investment of close to USD 80 million, anchored by LSP 7, with the participation of leading institutional investors, including Earlybird, Novartis Venture Fund, Pivotal bioVenture Partners, funds managed by Tekla Capital Management LLC, and VI Partners, among others. VISCHER AG has been advising Oculis since inception and is also in this business combination and the resulting listing on NASDAQ on all Swiss law aspects. The team is led by Matthias Staehelin with Christian Wyss, Vincent Reardon, Balthasar Müller (all Corporate/M&A), Marc Prinz (Employment) as well as Nadia Tarolli and Adrian Briner (both Tax).
Category: Life Sciences, Pharma, Biotech
Attorney at Law and Civil Law Notary
Attorney at Law
Attorney at Law, Swiss Certified Tax Expert (2008)
Anokion SA, a clinical-stage biotechnology company focused on treating autoimmune disease by...
Norgine Ventures has provided financing of approx. EUR 10 million to Lunaphore Technologies.
Versantis, a private Swiss-based clinical stage biotechnology company focused on addressing the...
Opt-in for our regular updates, news, views, insights and more.